Business

Onward Technologies Sustains Growth Momentum in Q2FY26; Total Revenue up 12.4% YoY to INR 140.1 Crore, EBITDA Margin at Record 14.3%

Oct 17, 2025

BusinessWire India
Mumbai (Maharashtra) [India], October 17: Onward Technologies Limited (BSE: 517536) (NSE: ONWARDTEC), a software outsourcing company, specializing in digital and ER&D services, announced today its financial results for the Second Quarter of FY26 ended on 30th September 2025.
Commenting on the results, Mr. Jigar Mehta, Managing Director, Onward Technologies, said, "Q2FY26 marks a milestone for us, with revenue and EBITDA margin reaching the highest levels in the company's history. We are pleased to report consolidated total revenue of INR140.1 crore, reflecting a YoY increase of 12.4%. Our EBITDA margin expanded by 789 bps YoY to 14.3%, while PAT grew by 230.6% YoY, with PAT margin improving by 563 bps to 8.6% during the quarter.
This performance highlights our continued focus on deepening relationships with strategic clients in the US and Europe and enhancing our capabilities across key service areas. We continue to invest in talent, technology, and innovation to create long-term value for all stakeholders."

Key Highlights - Q2 FY26
* Q2FY26 total revenue was at INR 140.1 crore, reflecting a growth of 12.4% YoY.
* Continued to maintain momentum in its focused verticals in Q2FY26:
-Industrial Equipment & Heavy Machinery (IEHM) contributed 63% of consolidated revenues.
-Transportation & Mobility (T&M) accounted for 34% of consolidated revenues.
-Healthcare & Life Sciences (HCLS) contributed 3% of consolidated revenues.
* Top 25 clients contribute 87% of total revenues.
* Total headcount stood at 2525 employees.
* Attrition at 15.49% (LTM).
(ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same)

More news

Clinicians at Fortis' S.L. Raheja Hospital Successfully Perform 1st Bone Marrow Transplant, Marking a Major Milestone in Advanced Cancer Care

Mumbai (Maharashtra) [India], October 20: S.L. Raheja Hospital, Mahim - A Fortis Associate, has achieved a milestone in its clinical journey with the successful completion of its first-ever Bone Marrow Transplant (BMT) at the COE for Haemato-Oncology. The landmark procedure was performed on a critically ill 61-year-old patient named Bijayentimala Devi from Manipur diagnosed with Multiple Myeloma, a complex form of blood cancer. The patient underwent an autologous stem cell transplant, which has led to a remarkable improvement in health, weight gain, and overall well-being -- bringing renewed hope to patients suffering from serious haematological conditions.

Oct 20, 2025